Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis

Janet F. Eary; Finbarr O'Sullivan; Yudi Powitan; Kingshuk Chandhury; Cheryl Vernon; James D. Bruckner; Ernest U. Conrad

doi:10.1007/s00259-002-0859-5

Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis

Janet F. Eary
, Finbarr O'Sullivan
, Yudi Powitan
, Kingshuk Chandhury
, Cheryl Vernon
, James D. Bruckner
, Ernest U. Conrad

School of Mathematical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

In a retrospective analysis of patients with sarcoma who underwent fluorodeoxyglucose positron emission tomography (FDG PET) imaging, tumor maximum FDG uptake was analyzed for ability to predict patient survival and disease-free interval. Two hundred and nine patients with sarcoma were imaged prior to treatment with neoadjuvant chemotherapy or resection. Tumor FDG uptake expressed as maximum standard uptake value (SUV_max) was compared with disease-free and overall survival. A multivariate Cox regression analysis was applied to examine the role of SUV_max in predicting time to death or disease progression, after adjusting for standard clinical prognostic factors. The multivariate analyses showed that the SUV_max information is a statistically significant independent predictor of patient survival. Tumors with larger SUV_max have a significantly poorer prognosis. This retrospective analysis indicates that the sarcoma tumor SUV_max value determined by PET is an independent predictor of survival and disease progression.

Original language	English
Pages (from-to)	1149-1154
Number of pages	6
Journal	European Journal of Nuclear Medicine
Volume	29
Issue number	9
DOIs	https://doi.org/10.1007/s00259-002-0859-5
Publication status	Published - 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Disease-free interval
FDG PET
Sarcoma
Survival
SUV

Access to Document

10.1007/s00259-002-0859-5

Cite this

@article{8ca2a7380b23491b978ccfd36bf52c6d,

title = "Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis",

abstract = "In a retrospective analysis of patients with sarcoma who underwent fluorodeoxyglucose positron emission tomography (FDG PET) imaging, tumor maximum FDG uptake was analyzed for ability to predict patient survival and disease-free interval. Two hundred and nine patients with sarcoma were imaged prior to treatment with neoadjuvant chemotherapy or resection. Tumor FDG uptake expressed as maximum standard uptake value (SUVmax) was compared with disease-free and overall survival. A multivariate Cox regression analysis was applied to examine the role of SUVmax in predicting time to death or disease progression, after adjusting for standard clinical prognostic factors. The multivariate analyses showed that the SUVmax information is a statistically significant independent predictor of patient survival. Tumors with larger SUVmax have a significantly poorer prognosis. This retrospective analysis indicates that the sarcoma tumor SUVmax value determined by PET is an independent predictor of survival and disease progression.",

keywords = "Disease-free interval, FDG PET, Sarcoma, Survival, SUV",

author = "Eary, \{Janet F.\} and Finbarr O'Sullivan and Yudi Powitan and Kingshuk Chandhury and Cheryl Vernon and Bruckner, \{James D.\} and Conrad, \{Ernest U.\}",

year = "2002",

doi = "10.1007/s00259-002-0859-5",

language = "English",

volume = "29",

pages = "1149--1154",

journal = "European Journal of Nuclear Medicine",

issn = "0340-6997",

publisher = "Springer",

number = "9",

}

TY - JOUR

T1 - Sarcoma tumor FDG uptake measured by PET and patient outcome

T2 - A retrospective analysis

AU - Eary, Janet F.

AU - O'Sullivan, Finbarr

AU - Powitan, Yudi

AU - Chandhury, Kingshuk

AU - Vernon, Cheryl

AU - Bruckner, James D.

AU - Conrad, Ernest U.

PY - 2002

Y1 - 2002

N2 - In a retrospective analysis of patients with sarcoma who underwent fluorodeoxyglucose positron emission tomography (FDG PET) imaging, tumor maximum FDG uptake was analyzed for ability to predict patient survival and disease-free interval. Two hundred and nine patients with sarcoma were imaged prior to treatment with neoadjuvant chemotherapy or resection. Tumor FDG uptake expressed as maximum standard uptake value (SUVmax) was compared with disease-free and overall survival. A multivariate Cox regression analysis was applied to examine the role of SUVmax in predicting time to death or disease progression, after adjusting for standard clinical prognostic factors. The multivariate analyses showed that the SUVmax information is a statistically significant independent predictor of patient survival. Tumors with larger SUVmax have a significantly poorer prognosis. This retrospective analysis indicates that the sarcoma tumor SUVmax value determined by PET is an independent predictor of survival and disease progression.

AB - In a retrospective analysis of patients with sarcoma who underwent fluorodeoxyglucose positron emission tomography (FDG PET) imaging, tumor maximum FDG uptake was analyzed for ability to predict patient survival and disease-free interval. Two hundred and nine patients with sarcoma were imaged prior to treatment with neoadjuvant chemotherapy or resection. Tumor FDG uptake expressed as maximum standard uptake value (SUVmax) was compared with disease-free and overall survival. A multivariate Cox regression analysis was applied to examine the role of SUVmax in predicting time to death or disease progression, after adjusting for standard clinical prognostic factors. The multivariate analyses showed that the SUVmax information is a statistically significant independent predictor of patient survival. Tumors with larger SUVmax have a significantly poorer prognosis. This retrospective analysis indicates that the sarcoma tumor SUVmax value determined by PET is an independent predictor of survival and disease progression.

KW - Disease-free interval

KW - FDG PET

KW - Sarcoma

KW - Survival

KW - SUV

UR - https://www.scopus.com/pages/publications/0036367410

U2 - 10.1007/s00259-002-0859-5

DO - 10.1007/s00259-002-0859-5

M3 - Article

C2 - 12192559

AN - SCOPUS:0036367410

SN - 0340-6997

VL - 29

SP - 1149

EP - 1154

JO - European Journal of Nuclear Medicine

JF - European Journal of Nuclear Medicine

IS - 9

ER -

Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this